Business
Publication highlights advantages of EpiSwitchT
Publication highlights advantages of EpiSwitchT.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 6134G Oxford BioDynamics PLC 31 May 2017 \n\n31 May 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nNature (Scientific Reports) publication highlights advantages of EpiSwitch™ technology platform\n \nOxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to note the peer reviewed publication of its collaborative work in the journal Nature (Scientific Reports) entitled: \"Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions\".1\n \nThe Scientific Report, published by the Cancer Science Institute of Singapore, National University of Singapore in collaboration with Oxford BioDynamics, is focused on cancer specific genome architecture and chromosomal conformations, with the interplay between histone modifications, gene regulation and long range interactions with super-enhancers, all facilitated through chromatin interactions, which were successfully monitored by Oxford BioDynamics' EpiSwitch™ platform.\n \nDr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented:\n \n\"Melissa Fullwood and her team at the Cancer Science Institute of Singapore are leading researchers in the field of regulatory genome architecture. We are pleased that they have chosen to complement their study with our EpiSwitch™ technology for the analysis of super-enhancers and H3K4me3 domain-associated chromatin interactions. EpiSwitch™ was used here to verify, at high resolution, originally observed long range chromosomal interactions in cell lines and, importantly, in patient clinical samples, for chronic myelogenous leukaemia. This successful collaboration is another good example of using the EpiSwitch™ platform as a practical tool for analysing and deconvoluting multiple epigenetic data sets for insights into genome regulation and genome architecture.\"\n \nThe full abstract of the paper can be found below.\n \nAbstract\n \nSuper-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving\nChromatin Interactions\n&nbs...